Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.64 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.57 |
| ▸ | ATR | Q13535 | 13/20 | 0.51 |
| ▸ | PRKDC | P78527 | 5/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11146891 | 0.87 | IKBKB (0.60) | IKBKBMAP2K3ATRPRKDCATM | |
| SCHEMBL6990771 | 0.86 | IKBKB (0.51) | IKBKBMAP2K3ATRPRKDCATM | |
| SCHEMBL24248259 | 0.83 | ATR (0.67) | IKBKBMAP2K3ATRPRKDCATM | |
| SCHEMBL3462610 | 0.81 | ATR (0.63) | IKBKBMAP2K3ATRPRKDCATM | |
| SCHEMBL2850738 | 0.80 | IKBKB (0.60) | IKBKBMAP2K3ATRPRKDCATM | |
| SCHEMBL3461817 | 0.80 | IKBKB (0.49) | IKBKBATRPRKDCATM | |
| SCHEMBL6987949 | 0.79 | IKBKB (0.51) | IKBKBMAP2K3ATRPRKDCATM | |
| Hydrochloric Acid SCHEMBL28324236 | 0.79 | IKBKB (0.58) | IKBKBMAP2K3ATRPRKDCATM | |
| SCHEMBL3461304 | 0.78 | IKBKB (0.74) | IKBKBMAP2K3ATRPRKDCATM | |
| SCHEMBL7545059 | 0.75 | IKBKB (0.55) | IKBKBMAP2K3ATRPRKDCATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100434079-C | Pyrazine nucleotide/pyrazine nucleoside analogue and medical application thereof | FUJIYAMA CHEMICAL IND CO LTD (JP) | 2008-11-19 | — | — | CN | disclosed |
| CN-1551777-A | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | 富山化学工业株式会社 | 2004-12-01 | — | — | CN | disclosed |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1417967-A1 | NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | CDK5, NT5C3B, CDK15 | IKBKB 3484/4885MAP2K3 927/4885ATR 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.